By Cristina Roca
Sanofi SA on Sunday reported positive results from a Phase 3 trial of its Sarclisa treatment in combination with other therapies in patients with relapsed multiple myeloma.
The French pharmaceutical company said patients showed significantly longer median progression-free survival when using Sarclisa on top of carfilzomib and dexamethasone.
Multiple myeloma is a hematologic malignancy that doesn't have a cure, Sanofi said. Relapsed multiple myeloma is the term for when the cancer returns after treatment or a period of remission.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
05-16-22 0138ET